Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy

Journal of Cellular Physiology

Volumn 233, Issue 9, 2018, Pages 6441-6457

  Nasiri, Hadi ^a,b   Valedkarimi, Zahra ^a,b   Aghebati Maleki, Leili ^a,b   Majidi, Jafar ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

antibody drug conjugate; cancer; monoclonal antibody; multiple drug resistance; targeted therapy

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; TRASTUZUMAB EMTANSINE; ANTIBODY CONJUGATE;

CANCER RESISTANCE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 85044335749     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.26435     Document Type: Review

References (191)

1. Adair, J. R., Howard, P. W., Hartley, J. A., Williams, D. G., & Chester, K. A. (2012). Antibody-drug conjugates-a perfect synergy. Expert Opinion on Biological Therapy, 12(9), 1191–1206.
2. Aghebati-Maleki, L., Bakhshinejad, B., Baradaran, B., Motallebnezhad, M., Aghebati-Maleki, A., Nickho, H., … Majidi, J. (2016). Phage display as a promising approach for vaccine development. Journal of Biomedical Sciences, 23(1), 66.
3. Aghebati-Maleki, L., Majidi, J., Baradaran, B., Movassaghpour, A., & Abdolalizadeh, J. (2014). Generation and characterization of anti-CD34 monoclonal antibodies that react with hematopoietic stem cells. Cell Journal, 16(3), 361–366.
4. Aghebati-Maleki, L., Shabani, M., Baradaran, B., Motallebnezhad, M., Majidi, J., & Yousefi, M. (2017). Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia. Biomedicine and Pharmacotherapy, 88, 814–822.
5. Aghebati-Maleki, L., Younesi, V., Baradaran, B., Abdolalizadeh, J., Motallebnezhad, M., Nickho, H., … Yousefi, M. (2017). Antiproliferative and apoptotic effects of novel anti-ROR1 single-Chain antibodies in hematological malignancies. SLAS Discovery: Advancing Life Science R and D, 22(4), 408–417.
6. Albert, A. (1981). Chemotherapy: History and principles. Selective toxicity (pp. 180–234). Boston, MA: Springer.
7. Alderson, R. F., Kreitman, R., Chen, T., Yeung, P., Herbst, R., Fox, J., & Pastan, I. (2009). CAT-8015: A Second-Generation Pseudomonas Exotoxin A―Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies. Clinical Cancer Research, 15(3), 832–839.
8. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008). Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjugate Chemistry, 19(3), 759–765.
9. Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M., Law, C.-L., Senter, P. D., & Benjamin, D. R. (2009). The pharmacologic basis for antibody-auristatin conjugate activity. Journal of Pharmacology and Experimental Therapeutics, 330(3), 932–938.
10. Apostolidou, E., Cortes, J., Tsimberidou, A., Estey, E., Kantarjian, H., & Giles, F. J. (2003). Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leukemia Research, 27(10), 887–891.
11. Baraldi, P. G., Bovero, A., Fruttarolo, F., Preti, D., Tabrizi, M. A., Pavani, M. G., & Romagnoli, R. (2004). DNA minor groove binders as potential antitumor and antimicrobial agents. Medicinal Research Reviews, 24(4), 475–528.
12. Baxter, L. T., & Jain, R. K. (1989). Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvascular Research, 37(1), 77–104.
13. Boger, D. L., & Johnson, D. S. (1995). CC-1065 and the duocarmycins: Unraveling the keys to a new class of naturally derived DNA alkylating agents. Proceedings of the National Academy of Sciences, 92(9), 3642–3649.
14. Boger, D. L., Patane, M. A., Jin, Q., & Kitos, P. A. (1994). Design, synthesis and evaluation of bouvardin, deoxybouvardin and RA-I-XIV pharmacophore analogs. Bioorganic and Medicinal Chemistry, 2(2), 85–100.
15. Burke, J. M., Jurcic, J. G., & Scheinberg, D. A. (2002). Radioimmunotherapy for acute leukemia. Cancer Control, 9(2), 106–113.
16. Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., … Girish, S. (2011). Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. Journal of Clinical Oncology, 29(4), 398–405.
17. Caron, P. C., Bull, M. K., Avdalovic, N. M., Queen, C., & Scheinberg, D. A. (1992). Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Research, 52(24), 6761–6767.
18. Carter, P. J., & Senter, P. D. (2008). Antibody-drug conjugates for cancer therapy. The Cancer Journal, 14(3), 154–169.
19. Casazza, A., Firestone, R., Hellstrom, I., & Hellstrom, K. (1993). Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science, 261, 9.
20. Casi, G., & Neri, D. (2012). Antibody-drug conjugates: Basic concepts, examples and future perspectives. Journal of Controlled Release, 161(2), 422–428.
21. Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., … Reman, O. (2012). Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. The Lancet, 379(9825), 1508–1516.
22. Chari, R. (2008). Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Accounts of Chemical Research, 41(1), 98.
23. Chari, R. V. (1998). Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy. Advanced Drug Delivery Reviews, 31(1), 89–104.
24. Chari, R. V. (2007). Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Accounts of Chemical Research, 41(1), 98–107.
25. Chudasama, V., Maruani, A., & Caddick, S. (2016). Recent advances in the construction of antibody-drug conjugates. Nature Chemistry, 8(2), 114–119.
26. Cianfriglia, M., Mallano, A., Ascione, A., & Dupuis, M. L. (2010). Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-γ1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. International Journal of Oncology, 36(6), 1513.
27. de Goeij, B. E., & Lambert, J. M. (2016). New developments for antibody-drug conjugate-based therapeutic approaches. Current Opinion in Immunology, 40, 14–23.
28. Deckert, P. (2009). Current constructs and targets in clinical development for antibody-based cancer therapy. Current Drug Targets, 10(2), 158–175.
29. DeVita, V. T., & Chu, E. (2008). A history of cancer chemotherapy. Cancer Research, 68(21), 8643–8653.
30. Diamantis, N., & Banerji, U. (2016). Antibody-drug conjugates-an emerging class of cancer treatment. British Journal of Cancer, 114(4), 362–367.
31. Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., … Junutula, J. R. (2009). Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood, 114(13), 2721–2729.
32. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., … Zabinski, R. F. (2006). Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjugate Chemistry, 17(1), 114–124.
33. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., … Siegall, C. B. (2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology, 21(7), 778–784.
34. Drachman, J. G., & Senter, P. D. (2013). Antibody-drug conjugates: The chemistry behind empowering antibodies to fight cancer. Hematology. American Society of Hematalogy. Education Program, 2013(1), 306–310.
35. Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006). Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. Journal of the National Cancer Institute, 98(5), 335–344.
36. Ducry, L., & Stump, B. (2010). Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjugate Chemistry, 21(1), 5.
37. Dumontet, C., & Jordan, M. A. (2010). Microtubule-binding agents: A dynamic field of cancer therapeutics. Nature Reviews Drug Discovery, 9(10), 790–803.
38. Ehrlich, P. (1956). The relationship existing between chemical constitution, distribution, and pharmacological action. In: Himmelweit, F. (Ed.) The collected papers of Paul Ehrlich (Vol. 1 pp. 596–618). London: Pergamon Press.
39. Ehrlich, P. R., & Himmelweit, F. (1956). The collected papers of Paul Ehrlich. London, New York: Pergamon.
40. Elias, D. J., Kline, L. E., Robbins, B. A., Johnson, H., Jr, Pekny, K., Benz, M., … Dillman, R. O. (1994). Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. American Journal of Respiratory and Critical Care Medicine, 150(4), 1114–1122.
41. Erickson, H., Widdison, W., Mayo, M., Whiteman, K., Audette, C., Wilhelm, S., & Singh, R. (2010). Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjugate Chemistry, 21(1), 84.
42. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., … Blättler, W. A. (2006). Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Research, 66(8), 4426–4433.
43. Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016). Cancer immunotherapy: The beginning of the end of cancer? BMC Medicine, 14(1), 73.
44. Feld, J., Barta, S. K., Schinke, C., Braunschweig, I., Zhou, Y., & Verma, A. (2013). Linked-in: Design and efficacy of antibody drug conjugates in oncology. Oncotarget, 4(3), 397.
45. Flygare, J. A., Pillow, T. H., & Aristoff, P. (2013). Antibody-drug conjugates for the treatment of cancer. Chemical Biology and Drug Design, 81(1), 113–121.
46. Francisco, J., Cerveny, C., Meyer, D., Mixan, B., Klussman, K., Chace, D., … Toki, B. (2003). CAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood, 102(4), 1458–1465.
47. Gaynor, E. R., Unger, J. M., Miller, T. P., Grogan, T. M., White, L. A., Jr, Mills, G. M., … Fisher, R. I. (2001). Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group Study. Journal of Clinical Oncology, 19(3), 750–755.
48. Giroux, S. (2013). Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK, and BRAF. Bioorganic and Medicinal Chemistry Letters, 23(2), 394–401.
49. Goldmacher, V. S., & Kovtun, Y. V. (2011). Antibody-drug conjugates: Using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Therapeutic Delivery, 2(3), 397–416.
50. Goldman, B. (2003). Multidrug resistance: Can new drugs help chemotherapy score against cancer? Journal of the National Cancer Institute, 95(4), 255–257.
51. Goodman, L. S., Wintrobe, M. M., Dameshek, W., Goodman, M. J., Gilman, A., & McLennan, M. T. (1946). Nitrogen mustard therapy: Use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. Journal of the American Medical Association, 132(3), 126–132.
52. Gottesman, M. M., Pastan, I., & Ambudkar, S. V. (1996). P-glycoprotein and multidrug resistance. Current Opinion in Genetics and Development, 6(5), 610–617.
53. Guillemard, V., & Saragovi, H. U. (2004). Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene, 23(20), 3613–3621.
54. Haag, P., Viktorsson, K., Lindberg, M. L., Kanter, L., Lewensohn, R., & Stenke, L. (2009). Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Experimental Hematology, 37(6), 755–766.
55. Hamann, P. R., Hinman, L. M., Beyer, C. F., Greenberger, L. M., Lin, C., Lindh, D., … Upeslacis, J. (2005). An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjugate Chemistry, 16(2), 346–353.
56. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.
57. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
58. Hartley, J. A. (2011). The development of pyrrolobenzodiazepines as antitumour agents. Expert Opinion on Investigational Drugs, 20(6), 733–744.
59. Hughes, B. (2010). Antibody-drug conjugates for cancer: Poised to deliver? Nature Reviews Drug Discovery, 9(9), 665–667.
60. Jain, R. K., & Baxter, L. T. (1988). Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Research, 48(24 Part 1), 7022–7032.
61. Jaracz, S., Chen, J., Kuznetsova, L. V., & Ojima, I. (2005). Recent advances in tumor-targeting anticancer drug conjugates. Bioorganic and Medicinal Chemistry, 13(17), 5043–5054.
62. Jedema, I., Barge, R., Van Der Velden, V., Nijmeijer, B., Van Dongen, J., Willemze, R., & Falkenburg, J. (2004). Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: Rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia, 18(2), 316–325.
63. Jeffrey, S. C., Andreyka, J. B., Bernhardt, S. X., Kissler, K. M., Kline, T., Lenox, J. S., … Stone, I. J. (2006). Development and properties of β-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjugate Chemistry, 17(3), 831–840.
64. Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., … Nicholas, N. D. (2013). A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjugate Chemistry, 24(7), 1256–1263.
65. Jeffrey, S. C., Torgov, M. Y., Andreyka, J. B., Boddington, L., Cerveny, C. G., Denny, W. A., … Kline, T. (2005). Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. Journal of Medicinal Chemistry, 48(5), 1344–1358.
66. Jilani, I., Estey, E., Huh, Y., Joe, Y., Manshouri, T., Yared, M., … Thomas, D. (2002). Differences in CD33 intensity between various myeloid neoplasms. American Journal of Clinical Pathology, 118(4), 560–566.
67. Jin, W., Trzupek, J. D., Rayl, T. J., Broward, M. A., Vielhauer, G. A., Weir, S. J., … Boger, D. L. (2007). A unique class of duocarmycin and CC-1065 analogues subject to reductive activation. Journal of the American Chemical Society, 129(49), 15391–15397.
68. Kam, Y., Das, T., Minton, S., & Gatenby, R. A. (2014). Evolutionary strategy for systemic therapy of metastatic breast cancer: Balancing response with suppression of resistance. Women's Health, 10(4), 423–430.
69. Kartner, N., Evernden-Porelle, D., Bradley, G., & Ling, V. (1985). Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature, 316(6031), 820–823.
70. Kasten, F. H. (1996). Paul Ehrlich: Pathfinder in Cell Biology 1. Chronicle of His Life and Accomplishments in Immunology, Cancer Research, and Chemotherapy1: Paul Ehrlich's Recipe for Success: “Patience, Ability, Money, and Luck.” Biotechnic and Histochemistry, 71(1), 2–37.
71. Kell, W. J., Burnett, A. K., Chopra, R., Yin, J. A., Clark, R. E., Rohatiner, A., … Milligan, D. W. (2003). A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood, 102(13), 4277–4283.
72. Kellogg, B. A., Garrett, L., Kovtun, Y., Lai, K. C., Leece, B., Miller, M., … Widdison, W. (2011). Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjugate Chemistry, 22(4), 717–727.
73. Kigawa, J., Minagawa, Y., Kanamori, Y., Itamochi, H., Cheng, X., Okada, M., … Terakawa, N. (1998). Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer, 82(4), 697.
74. Kim, E. G., & Kim, K. M. (2015). Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomolecules and Therapeutics, 23(6), 493–509.
75. Klein, I., Sarkadi, B., & Váradi, A. (1999). An inventory of the human ABC proteins. Biochimica Et Biophysica Acta, 1461(2), 237.
76. Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., … Kallionimeni, O.-P. (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine, 4(7), 844–847.
77. Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., … Ab, O. (2010). Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Research, 70(6), 2528–2537.
78. Kreuter, J. (2007). Nanoparticles-a historical perspective. International Journal of Pharmaceutics, 331(1), 1–10.
79. Kruser, T. J., & Wheeler, D. L. (2010). Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research, 316(7), 1083–1100.
80. Laguzza, B. C., Nichols, C. L., Briggs, S. L., Cullinan, G. J., Johnson, D. A., Starling, J. J., … Corvalan, J. R. (1989). New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation, and representative in vivo activity. Journal of Medicinal Chemistry, 32(3), 548–555.
81. Lambert, J. M. (2005). Drug-conjugated monoclonal antibodies for the treatment of cancer. Current Opinion in Pharmacology, 5(5), 543–549.
82. Leal, M., Sapra, P., Hurvitz, S. A., Senter, P., Wahl, A., Schutten, M., … Kabbarah, O. (2014). Antibody-drug conjugates: An emerging modality for the treatment of cancer. Annals of the New York Academy of Sciences, 1321(1), 41–54.
83. Legrand, O., Zittoun, R., & Marie, J. (1999). Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia, 13, 578–584.
84. Lehne, G. (2000). P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Current Drug Targets, 1(1), 85–99.
85. Linenberger, M., Hong, T., Flowers, D., Sievers, E., Gooley, T., Bennett, J., … Bernstein, I. (2001). Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood, 98(4), 988–994.
86. Liu, R., Wang, R. E., & Wang, F. (2016). Antibody-drug conjugates for non-oncological indications. Expert Opinion on Biological Therapy, 16(5), 591–593.
87. LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011). Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clinical Cancer Research, 17(20), 6437–6447.
88. Lu, J., Jiang, F., Lu, A., & Zhang, G. (2016). Linkers having a crucial role in antibody-drug conjugates. International Journal of Molecular Sciences, 17(4), 561.
89. Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., … Senter, P. D. (2015). Reducing hydrophobicity of homogeneous antibody-Drug conjugates improves pharmacokinetics and therapeutic index. Nature Biotechnology, 33(7), 733–735.
90. Mack, F., Ritchie, M., & Sapra, P. (2014). The next generation of antibody drug conjugates. Seminars in Oncology, 41(5), 637–52.
91. Maleki, L. A., Baradaran, B., Majidi, J., Mohammadian, M., & Shahneh, F. Z. (2013). Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Human Antibodies, 22(1-2), 9–13.
92. Maleki, L. A., Majidi, J., Baradaran, B., Abdolalizadeh, J., & Akbari, A. M. (2013). Production and characterization of murine monoclonal antibody against synthetic peptide of CD34. Human Antibodies, 22(1-2), 1–8.
93. Maleki, L. A., Majidi, J., Baradaran, B., Abdolalizadeh, J., Kazemi, T., & Maleki, A. A. (2013). Large scale generation and characterization of anti-Human CD34 monoclonal antibody in ascetic fluid of balb/c mice. Advance Pharmaceutical Bulletin, 3(1), 211–216.
94. Mao, W., Luis, E., Ross, S., Silva, J., Tan, C., Crowley, C., … Koeppen, H. (2004). EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Research, 64(3), 781–788.
95. Matsui, H., Takeshita, A., Naito, K., Shinjo, K., Shigeno, K., Maekawa, M., … Ohnishi, K. (2002). Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia, (08876924) 16(5).
96. Matsumoto, T., Jimi, S., Hara, S., Takamatsu, Y., Suzumiya, J., & Tamura, K. (2012). Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. Leukemia and Lymphoma, 53(7), 1399–1405.
97. Mirza, A. Z., & Siddiqui, F. A. (2014). Nanomedicine and drug delivery: A mini review. International Nano Letters, 4(1), 94.
98. Moldenhauer, G., Salnikov, A. V., Lüttgau, S., Herr, I., Anderl, J., & Faulstich, H. (2012). Therapeutic potential of amanitin-Conjugated anti-Epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. Journal of the National Cancer Institute, 104(8).
99. Moore, J., Seiter, K., Kolitz, J., Stock, W., Giles, F., Kalaycio, M., … Marcucci, G. (2006). A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leukemia Research, 30(7), 777–783.
100. Motallebnezhad, M., Younesi, V., Aghebati-Maleki, L., Nickho, H., Safarzadeh, E., Ahmadi, M., … Yousefi, M. (2016). Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells. Tumour Biology, 37(11), 14841–14850.
101. Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010). Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery, 9(10), 767–774.
102. Nickho, H., Younesi, V., Aghebati-Maleki, L., Motallebnezhad, M., Majidi Zolbanin, J., Movassagh Pour, A., & Yousefi, M. (2017). Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor. Bioengineered, 8(5), 501–510.
103. Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012). Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Medicinal Research Reviews, 32(6), 1220–1262.
104. Nolting, B. (2013). Linker technologies for antibody-drug conjugates. Methods in Molecular Biology (Clifton, N.J.), 1045, 71–100.
105. O'Brien, C., Cavet, G., Pandita, A., Xiaolan, H., Haydu, L., Mohan, S., … Amler, L. C. (2008). Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-Amplified Breast cancer. Cancer Research, 68(13), 5380–5389.
106. O'Mahony, D., & Bishop, M. (2006). Monoclonal antibody therapy. Frontiers in Bioscience: A Journal and Virtual Library, 11, 1620–1635.
107. Orth, J., Krueger, E., Weller, S., & McNiven, M. (2006). A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Research, 66(7), 3603–3610.
108. Panchal, R. G. (1998). Novel therapeutic strategies to selectively kill cancer cells. Biochemical Pharmacology, 55(3), 247–252.
109. Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. 2014. Site-specific antibody drug conjugates for cancer therapy. MAbs, 6(1), 34–45.
110. Papachristou, D., Zaki, A., & Fortner, J. (1977). Chlorambucil-carrying ALG as an immunosuppressive agent in the rat. Transplantation Proceedings, 9(1), 1059–1062.
111. Parslow, A. C., Parakh, S., Lee, F.-T., Gan, H. K., & Scott, A. M. (2016). Antibody-Drug conjugates for cancer therapy. Biomedicines, 4(3), 14.
112. Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014). Antibody-drug conjugates: Current status and future directions. Drug Discovery Today, 19(7), 869–881.
113. Peters, S. A. (2012). Physiologically-based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry. John Wiley & Sons.
114. Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., … Stuart, R. K. (2013). A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood, 121(24), 4854.
115. Petersen, B. H., DeHerdt, S. V., Schneck, D. W., & Bumol, T. F. (1991). The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Research, 51(9), 2286–2290.
116. Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D., Schaefer, G., Miller, K., … Harbeck, N. (2014). Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy. Clinical Cancer Research, 20(2), 456–468.
117. Pietersz, G., & Krauer, K. (1994). Antibody-targeted drugs for the therapy of cancer. Journal of Drug Targeting, 2(3), 183–215.
118. Polakis, P. (2016). Antibody drug conjugates for cancer therapy. Pharmacological Reviews, 68(1), 3–19.
119. Polson, A., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., … Elliott, J. (2009). Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: Target and linker-drug selection. Cancer Research, 69(6), 2358–2364.
120. Polson, A. G., Ho, W. Y., & Ramakrishnan, V. (2011). Investigational antibody-drug conjugates for hematological malignancies. Expert Opinion on Investigational Drugs, 20(1), 75–85.
121. Reichert, J. M. 2014. Antibodies to watch in 2014. MAbs, 6(1), 5–14.
122. Remillard, S., Rebhun, L. I., Howie, G. A., & Kupchan, S. M. (1975). Antimitotic activity of the potent tumor inhibitor maytansine. Science, 189(4207), 1002–1005.
123. Reslan, L., Dalle, S., & Dumontet, C. (2009). Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs. 1(3), 222–229.
124. Rezaei, N., Aalaei-Andabili, S. H., & Kaufman, H. L. (2015). Introduction on cancer immunology and immunotherapy. Cancer immunology (pp. 1–8). Berlin, Heidelberg: Springer.
125. Ricart, A. D. (2011). Antibody-Drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin. Clinical Cancer Research, 17(20), 6417–6427.
126. Ricart, A. D., & Tolcher, A. W. (2007). Technology insight: Cytotoxic drug immunoconjugates for cancer therapy. Nature Clinical Practice Oncology, 4(4), 245–255.
127. Ritchie, M., Tchistiakova, L., & Scott, N. (2013). Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs, 5(1), 13–21.
128. Rohrer, T. (2008). New weapons for the oncology arsenal. Chemistry Rundschau, 9, 26–28.
129. Rosenberg, A. S. (2006). Effects of protein aggregates: An immunologic perspective. The AAPS Journal, 8(3), E501.
130. Rosenzweig, S. A. (2012). Acquired resistance to drugs targeting receptor tyrosine kinases. Biochemical Pharmacology, 83(8), 1041–1048.
131. Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J., Weiner, L. M., … Adams, G. P. (2011). Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Research, 71(6), 2250–2259.
132. Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M., Doronina, S. O., Siadak, A. W., … Wahl, A. F. (2005). In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clinical Cancer Research, 11(2), 843–852.
133. Sapra, P., Hooper, A. T., O'Donnell, C. J., & Gerber, H.-P. (2011). Investigational antibody drug conjugates for solid tumors. Expert Opinion on Investigational Drugs, 20(8), 1131–1149.
134. Schmidt, M. M., & Wittrup, K. D. (2009). A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Molecular Cancer Therapeutics, 8(10), 2861–2871.
135. Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C. (1985). Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Research, 45(2), 879–885.
136. Schumacher, D., Hackenberger, C. P., Leonhardt, H., & Helma, J. (2016). Current status: Site-specific antibody drug conjugates. Journal of Clinical Immunology, 36(1), 100–107.
137. Scott, A. M., Lee, F.-T., Tebbutt, N., Herbertson, R., Gill, S. S., Liu, Z., … Chappell, B. (2007). A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proceedings of the National Academy of Sciences, 104(10), 4071–4076.
138. Scott, A. M., Wolchok, J. D., & Old, L. J. (2012). Antibody therapy of cancer. Nature Reviews Cancer, 12(4), 278–287.
139. Sedlacek, H. H., Seemann, G., Hoffmann, D., Czech, J., Lorenz, P., Kolar, C., & Bosslet, K. (1992). Antibodies as carriers of cytotoxicity. Basel, New York: Karger.
140. Senter, P. D. (2009). Potent antibody drug conjugates for cancer therapy. Current Opinion in Chemical Biology, 13(3), 235–244.
141. Senter, P. D., & Sievers, E. L. (2012). The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnology, 30(7), 631–637.
142. Shah, M. A. (2015). Update on metastatic gastric and esophageal cancers. Journal of Clinical Oncology, 33(16), 1760–1769.
143. Sharom, F. J. (2008). ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics, 9(1), 105–127.
144. Shefet-Carasso, L., & Benhar, I. (2015). Antibody-targeted drugs and drug resistance-challenges and solutions. Drug Resistance Updates, 18, 36–46.
145. Shih, L. B., Goldenberg, D. M., Xuan, H., Lu, H. W.-Z., Mattes, M. J., & Hall, T. C. (1994). Internalization of an intact doxorubicin immunoconjugate. Cancer Immunology, Immunotherapy, 38(2), 92–98.
146. Shuptrine, C. W., Surana, R., & Weiner, L. M. Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology, 22(1): 3–13.
147. Sierra, J. R., Cepero, V., & Giordano, S. (2010). Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Molecular Cancer, 9, 75.
148. Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., … Sherman, M. L. (2001). Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19(13), 3244–3254.
149. Sievers, E. L., & Linenberger, M. (2001). Mylotarg: Antibody-targeted chemotherapy comes of age. Current Opinion in Oncology, 13(6), 522–527.
150. Sievers, E. L., & Senter, P. D. (2013). Antibody-drug conjugates in cancer therapy. Annual Review of Medicine, 64, 15–29.
151. Silva, A. S., Kam, Y., Khin, Z. P., Minton, S. E., Gillies, R. J., & Gatenby, R. A. (2012). Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Research, 72(24), 6362–6370.
152. Singh, Y., Palombo, M., & Sinko, P. J. (2008). Recent trends in targeted anticancer prodrug and conjugate design. Current Medicinal Chemistry, 15(18), 1802–1826.
153. Smyth, M., Pietersz, G., & McKenzie, I. (1987). The mode of action of methotrexate-monoclonal antibody conjugates. Immunology and Cell Biology, 65, 189.
154. Strebhardt, K., & Ullrich, A. (2008). Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer, 8(6), 473–480.
155. Sussman, D., Smith, L. M., Anderson, M. E., Duniho, S., Hunter, J. H., Kostner, H., … Van Epps, H. A. (2014). SGN-LIV1A: A novel antibody-Drug conjugate targeting LIV-1 for the treatment of metastatic Breast cancer. Molecular Cancer Therapeutics, 13(12), 2991–3000.
156. Sutherland, M. S. K., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., … Lyon, R. P. (2013). SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood, 122(8), 1455–1463.
157. Suzawa, T., Nagamura, S., Saito, H., Ohta, S., Hanai, N., & Yamasaki, M. (2000). Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly (ethylene glycol)-dipeptidyl linker capable of tumor specific activation. Bioorganic and Medicinal Chemistry, 8(8), 2175–2184.
158. Takara, K., Sakaeda, T., & Okumura, K. (2006). An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Current Pharmaceutical Design, 12(3), 273–286.
159. Takeshita, A. (2013). Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia. International Journal of Hematology, 97(6), 703–716.
160. Takeshita, A., Shinjo, K., Yamakage, N., Ono, T., Hirano, I., Matsui, H., … Maekawa, M. (2009). CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. British Journal of Haematology, 146(1), 34.
161. Takeshita, A., Yamakage, N., Shinjo, K., Ono, T., Hirano, I., Nakamura, S., … Kiyoi, H. (2009). CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia, 23(7), 1329–1336.
162. Tang, R., Cohen, S., Perrot, J.-Y., Faussat, A.-M., Zuany-Amorim, C., Marjanovic, Z., … Legrand, O. (2009). P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer, 9(1), 199.
163. Teicher, B. (2009). Antibody-drug conjugate targets. Current Cancer Drug Targets, 9(8), 982–1004.
164. Teicher, B. A., & Chari, R. V. (2011). Antibody conjugate therapeutics: Challenges and potential. Clinical Cancer Research, 17(20), 6389–6397.
165. Ten Cate, B., Bremer, E., De Bruyn, M., Bijma, T., Samplonius, D., Schwemmlein, M., … Helfrich, W. (2009). A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia, 23(8), 1389–1397.
166. Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008). Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Advanced Drug Delivery Reviews, 60(12), 1421–1434.
167. Tsimberidou, A., Cortes, J., Thomas, D., Garcia-Manero, G., Verstovsek, S., Faderl, S., … Giles, F. J. (2003). Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research, 27(10), 893–897.
168. Tsimberidou, A. M., Giles, F. J., Estey, E., O'brien, S., Keating, M. J., & Kantarjian, H. M. (2006). The role of gemtuzumab ozogamicin in acute leukaemia therapy. British Journal of Haematology, 132(4), 398–409.
169. Tsuchikama, K., & An, Z. (2018). Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein and Cell, 9(1), 33–46.
170. Tsuruo, T. (1988). Mechanisms of multidrug resistance and implications for therapy. Japanese Journal of Cancer Research, 79(3), 285–296.
171. Uadia, P., Blair, A. H., & Ghose, T. (1984). Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing mice. Cancer Research, 44(10), 4263–4266.
172. Ueda, K., Taguchi, Y., & Morishima, M. (1997). How does P-glycoprotein recognize its substrates? Seminars in Cancer Biology, 8(3), 151–159.
173. van der Kolk, D. M., de Vries, E. G., Müller, M., & Vellenga, E. (2002). The role of drug efflux pumps in acute myeloid leukemia. Leukemia and Lymphoma, 43(4), 685–701.
174. van der Velden, V. H., Boeckx, N., Jedema, I., te Marvelde, J. G., Hoogeveen, P. G., Boogaerts, M., & van Dongen, J. J. (2004). High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients. Leukemia, 18(5), 983–988.
175. Valedkarimi, Z., Nasiri, H., Aghebati-Maleki, L., & Majidi, J. (2017). Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy. Biomedicine and Pharmacotherapy, 95, 731–742.
176. Velden, V., Marvelde, J., Hoogeveen, P., Bernstein, I., Houtsmuller, A., Berger, M., & Dongen, J. (2001). Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 97(10), 3197–3204.
177. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., … Guardino, E. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367(19), 1783–1791.
178. Walter, R., Raden, B., Hong, T., Flowers, D., Bernstein, I., & Linenberger, M. (2003). Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood, 102(4), 1466.
179. Walter, R., Raden, B., Kamikura, D., Cooper, J., & Bernstein, I. (2005). Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood, 105(3), 1295.
180. Walter, R. B., Raden, B. W., Cronk, M. R., Bernstein, I. D., Appelbaum, F. R., & Banker, D. E. (2004). The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood, 103(11), 4276–4284.
181. Wang, W., Wang, E., & Balthasar, J. (2008). Monoclonal antibody pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics, 84(5), 548–558.
182. Weiner, L. M., Surana, R., & Wang, S. (2010). Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nature Reviews Immunology, 10(5), 317–327.
183. Wind, N., & Holen, I. (2011). Multidrug resistance in breast cancer: From in vitro models to clinical studies. International Journal of Breast Cancer, 2011.
184. Wu, A. M., & Senter, P. D. (2005). Arming antibodies: Prospects and challenges for immunoconjugates. Nature Biotechnology, 23(9), 1137–1146.
185. Xie, H., & Blättler, W. A. (2006). In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer. Expert Opinion on Biological Therapy, 6(3), 281–291.
186. Xu, C.-F., & Wang, J. (2015). Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences, 10(1), 1–12.
187. Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., … De Vos, S. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology, 30(18), 2183–2189.
188. Zdimerova, H., Albert, M. L., & Ingersoll, M. A. (2015). Harnessing the host immune response to Infection?BCG immunotherapy for bladder cancer. Infection and cancer: Bi-Directorial interactions. (pp. 387–403). Cham: Springer.
189. Zhao, R. Y., Erickson, H. K., Leece, B. A., Reid, E. E., Goldmacher, V. S., Lambert, J. M., & Chari, R. V. (2012). Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. Journal of Medicinal Chemistry, 55(2), 766–782.
190. Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., … Widdison, W. C. (2011). Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. Journal of Medicinal Chemistry, 54(10), 3606–3623.
191. Zhou, D., Zittoun, R., & Marie, J. (1995). Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia, 9(10), 1661–1666.